Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases

Patent metadata

Field	Value
Publication number	US-10995137-B2
Application number	US-201816475299-A
Country	US
Kind code	B2
Filing date	Jan 3, 2018
Priority date	Jan 4, 2017
Publication date	May 4, 2021
Grant date	May 4, 2021

Abstract

The present invention is based on antibodies which are both highly specific for hyperphosphorylated pathogenic P-S396 tau and highly specific for labelled sections of the human retina, as well as to methods of using these antibodies and their tau binding fragments in the treatment of retinoid amyloidosis, age related macular degeneration (ARMD), and glaucoma.

First claim

The invention claimed is:

1. A method of delaying the progression of a disorder of choroid and retina selected from the group consisting of retinoid amyloidosis, age related macular degeneration (ARMD), retinal ganglion cell neurodegeneration associated with optic neuropathies, including glaucoma, dry ARMD and exudative ARMD, in a patient, said method comprising reducing or attenuating the accumulation of pathological tau protein in said patient by administering an antibody capable of immunospecifically binding to the phosphorylated residue 396 of human tau (SEQ ID NO:1) such that the antibody or an epitope-binding fragment thereof does not substantially bind to SEQ ID NO:1 phosphorylated at residue 404 when residue 396 is not phosphorylated, wherein the antibody comprises:
(A) (a) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:31;
(b) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:4;
(c) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:5;
(d) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:6;
(e) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:7; and
(f) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:39; or

(B) (a) a heavy chain comprising the amino acid sequence of SEQ ID NO:11, and
(b) a light chain comprising the amino acid sequence of SEQ ID NO:12; or

(C) (a) a heavy chain comprising the amino acid sequence of SEQ ID NO:13, SEQ ID NO:14 or SEQ ID NO:15, and
(b) a light chain comprising the amino acid sequence of SEQ ID NO:12; or

(D) (a) a heavy chain comprising the amino acid sequence of SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, or SEQ ID NO: 24, and
(b) a light chain comprising the amino acid sequence of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 or SEQ ID NO:23; or

(E) (a) a Heavy Chain CDR1 comprising the amino acid sequence of SEQ ID NO:6,
(b) a Heavy Chain CDR2 comprising the amino acid sequence of SEQ ID NO:7;
(c) a Heavy Chain CDR3 comprising the amino acid sequence of SEQ ID NO:8; and
(d) a Light Chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, and SEQ ID NO:23; or

(F) (a) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:3;
(b) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:4;
(c) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:5;
(d) a Heavy Chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15; or

(G) (a) the amino acid sequence of any one of SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26; and SEQ ID NO:27; or
(H) (a) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:66;
(b) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:67;
(c) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:68;
(d) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:69;
(e) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:70; and
(f) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:71; or

(I) (a) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:74;
(b) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:75;
(c) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:76;
(d) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:77;
(e) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:78; and
(f) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:79; or

(J) (a) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:58;
(b) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:59;
(c) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:60;
(d) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:61;
(e) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:62; and
(f) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:63.

2. A method of treating, diagnosing or imaging a disorder of choroid and retina in a subject, said method comprising administering a monoclonal antibody, or an epitope-binding fragment thereof capable of immunospecifically binding to the phosphorylated residue 396 of human tau (SEQ ID NO:1), wherein the antibody comprises:
(a) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:31;
(b) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:4;
(c) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:5;
(d) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:6;
(e) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:7; and
(f) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:39.

3. A method of treating, diagnosing or imaging a disorder of choroid and retina in a subject, said method comprising administering a monoclonal antibody, or an epitope-binding fragment thereof capable of immunospecifically binding to the phosphorylated residue 396 of human tau (SEQ ID NO:1), wherein the antibody comprises:
(a) a heavy chain comprising the amino acid sequence of SEQ ID NO:11, and
(b) a light chain comprising the amino acid sequence of SEQ ID NO:12.

4. A method of treating, diagnosing or imaging a disorder of choroid and retina in a subject, said method comprising administering a monoclonal antibody, or an epitope-binding fragment thereof capable of immunospecifically binding to the phosphorylated residue 396 of human tau (SEQ ID NO:1), wherein the antibody comprises
(a) a heavy chain comprising the amino acid sequence of SEQ ID NO:13, SEQ ID NO:14 or SEQ ID NO:15, and
(b) a light chain comprising the amino acid sequence of SEQ ID NO:12.

5. A method of treating, diagnosing or imaging a disorder of choroid and retina in a subject, said method comprising administering a monoclonal antibody, or an epitope-binding fragment thereof capable of immunospecifically binding to the phosphorylated residue 396 of human tau (SEQ ID NO:1), wherein the antibody comprises
(a) a heavy chain comprising the amino acid sequence of SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, or SEQ ID NO: 24, and
(b) a light chain comprising the amino acid sequence of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 or SEQ ID NO:23.

6. A method of treating, diagnosing or imaging a disorder of choroid and retina in a subject, said method comprising administering a monoclonal antibody, or an epitope-binding fragment thereof capable of immunospecifically binding to the phosphorylated residue 396 of human tau (SEQ ID NO:1), wherein the antibody comprises:
(a) a Heavy Chain CDR1 comprising the amino acid sequence of SEQ ID NO:6,
(b) a Heavy Chain CDR2 comprising the amino acid sequence of SEQ ID NO:7; and
(c) a Heavy Chain CDR3 comprising the amino acid sequence of SEQ ID NO:8; and
(d) a Light Chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, and SEQ ID NO:23.

7. A method of treating, diagnosing or imaging a disorder of choroid and retina in a subject, said method comprising administering a monoclonal antibody, or an epitope-binding fragment thereof capable of immunospecifically binding to the phosphorylated residue 396 of human tau (SEQ ID NO:1), wherein the antibody comprises:
(a) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:3;
(b) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:4;
(c) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:5;
(d) a Heavy Chain c

Assignees

• H Lundbeck As

Inventors

• Pedersen Jan Torleif
• Pedersen Lars Østergaard
• Daechsel Justus Claus
• Asuni Ayodeji Abdur-Rasheed
• Rosenqvist Nina Helen

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K16/18 Primary

  against material from animals or humans · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title